title: A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.
abstract: OBJECTIVE
  Stage III colon cancer is currently treated as an entity with a unified therapeutic principle. The aim of the retrospective study is to explore the clinicopathological characteristics and outcomes of site-specific stage III colon cancers and the influences of tumor location on prognosis.
  
  
  METHODS
  Eight hundred ninety-five patients with stage III colon cancer treated with radical operation and subsequent adjuvant chemotherapy (5-fluorouracil/oxaliplatin) were divided into seven groups according to colon segment (cecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, and sigmoid colon). Expression of excision repair cross-complementing group 1 (ERCC1) and thymidylate synthase (TS) was examined by immunohistochemistry. We assessed if differences exist in patient characteristics and clinic outcomes between the seven groups.
  
  
  RESULTS
  There were significant differences in tumor differentiation (P < 0.001), T stage (P < 0.001), N stage (P < 0.001), American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) stage (P < 0.001), metachronous liver metastasis (P < 0.001), metachronous lung metastasis (P < 0.001), and ERCCI expression (P < 0.001) between the seven groups. Both 5-year recurrence-free survival (RFS) and 5-year overall survival (OS) exhibited significant differences (both P < 0.001) with survival gradually decreasing from cecum to sigmoid colon. Cox regression analyses identified that tumor location was an independent prognostic factor for RFS and OS.
  
  
  CONCLUSIONS
  Stage III colon cancer located proximally carried a poorer survival than that located distally. Different efficacies of FOLFOX adjuvant chemotherapy may be an important factor affecting survival of site-specific stage III colon cancers.
authors.affiliation: Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Junli
authors.initials: J
authors.lastname: Ma
authors.forename: Sai
authors.initials: S
authors.lastname: Zhang
authors.forename: Ganlu
authors.initials: G
authors.lastname: Deng
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Wu
authors.forename: Jingxuan
authors.initials: J
authors.lastname: He
authors.forename: Haiping
authors.initials: H
authors.lastname: Pei
authors.forename: Hong
authors.initials: H
authors.lastname: Shen
authors.forename: Shan
authors.initials: S
authors.lastname: Zeng
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002430:Cecal Neoplasms / Q000737:chemistry / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003106:Colon / Q000473:pathology; D003110:Colonic Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D004268:DNA-Binding Proteins / Q000032:analysis; D018572:Disease-Free Survival; D004720:Endonucleases / Q000032:analysis; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D012189:Retrospective Studies; D015996:Survival Rate; D013940:Thymidylate Synthase / Q000032:analysis
chemical_list: D004268:DNA-Binding Proteins; D009944:Organoplatinum Compounds; D013940:Thymidylate Synthase; C071447:ERCC1 protein, human; D004720:Endonucleases; D002955:Leucovorin; D005472:Fluorouracil